Phase I, open study to assess the effect of rifampicin, a marketed drug, on how the body handles the experimental drug cediranib in patients with advanced cancer.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
64
45 mg cediranib once daily from Days 1-7; cediranib 45 mg plus 600 mg rifampicin from Days 8-14; 45 mg cediranib once daily from Days 15-28; from Day 29 patients may continue on 45 mg cediranib or dose reduce.
Research Site
Edmonton, Alberta, Canada
Research Site
Montreal, Quebec, Canada
Research Site
Dundee, United Kingdom
Research Site
Glasgow, United Kingdom
To assess the steady-state PK parameters of cediranib in the presence and absence of rifampicin
Time frame: PK assessments to be taken until Day 28. Days 7 and 14 PK parameters used to assess the primary variables.
To assess the safety and tolerability of cediranib in the presence of rifampicin, by assessment of Adverse events (AEs) Laboratory findings, Vital signs, physical examination and Electrocardiogram.
Time frame: Until study drug is discountinued
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Research Site
London, United Kingdom
Research Site
London, United Kingdom